QUOTE AND NEWS
Benzinga  5 hrs ago  Comment 
In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Regeneron Pharmaceuticals (NASDAQ: REGN) with a Buy rating and $350.00 price target. In the report, Canaccord Genuity noted, “We are initiating...
Benzinga  7 hrs ago  Comment 
SeekingAlpha  Apr 9  Comment 
By William Meyers: Regeneron Pharmaceuticals (REGN) is a profitable and rapidly growing biotechnology company, with trailing earnings per share (EPS) of $3.78. Even so, at $300 per share it is 14.9% off its 52-week high of $352.49. That gives it...
Forbes  Apr 9  Comment 
In early trading on Wednesday, shares of Regeneron Pharmaceuticals (REGN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.9%.  Year to date, Regeneron Pharmaceuticals registers a 7.1% gain.
StreetInsider.com  Apr 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Regeneron+%28REGN%29+co-Founder+Shooter+to+Retire+as+Director/9354534.html for the full story.
StreetInsider.com  Apr 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+SNY%29%2C+Regeneron+%28REGN%29+Reports+Alirocumab+Phase+2+Met+Primary+Endpoint+in+Japanese+Patients/9336530.html for the full story.
StreetInsider.com  Mar 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Regeneron+%28REGN%29+to+Present+Alirocumab+Data+at+ACC+Annual+Session/9321407.html for the full story.
TheStreet.com  Mar 17  Comment 
NEW YORK (TheStreet) -- TheStreet's Jim Cramer looked at Hertz Global Holdings after the Financial Times reported a possible spinoff of Hertz' construction rental business. Cramer said the unit is worth about $4.5 billion. Shareholders should be...
Benzinga  Mar 17  Comment 
On Monday, Citigroup upgraded shares of Regeneron (NASDAQ: REGN) from Neutral to Buy and raised the price target from $342 to $390. Analyst Yaron Werber does not “anticipate finding a better entry point near term.” In the note, Werber cited...
Forbes  Mar 3  Comment 
In early trading on Monday, shares of Regeneron Pharmaceuticals (REGN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.4%. Year to date, Regeneron Pharmaceuticals, Inc. registers a 23.7% gain.
StreetInsider.com  Feb 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Regeneron+%28REGN%29+sBLA+for+EYLEA+Accepted+by+FDA/9205256.html for the full story.




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki